Symptoms include joint inflammation, fever, weight loss and a characteristic facial rash
Food noise quieted The constant mental pull toward food fades
Nestle, meanwhile, launched a brand called Vital Pursuits, targeting GLP-1 users and offering smaller portions, in May 2024
doi: 10.3389/fnbeh.2026.1805953 Received 06 February 2026 Revised 13 March 2026 Accepted 13 March 2026 Published 13 April 2026 Volume 20 - 2026 Edited by Emmanuel Darcq, Institut National de la Sant et de la Recherche Mdicale (INSERM), France Reviewed by Zhe Zhao, Max Planck Florida Institute for Neuroscience (MPFI), United States Madhawi Aldhwayan, King Saud University, Saudi Arabia Updates Copyright 2026 OConnor
Foundayo (orforglipron) is Eli Lilly's small-molecule oral GLP-1 receptor agonist, FDA-approved on April 1, 2026 for chronic weight management in adults with obesity or overweight with a weight-related condition